Loading
A phase 2 trial of Iruplinalkib in Non-small-cell lung cancer, run by Pingping Song, now recruiting.
Neoadjuvant WX-0593 in Resectable ALK-positive or ROS1-positive Non-small Cell Lung Cancer is a phase 2 interventional study registered as NCT05765877 by Pingping Song, with 26 participants planned, started 2023-03-01 and due to reach its primary completion in 2027-03. Interventions recorded: WX-0593 Tablets. Conditions recorded: Non-Small Cell Lung Cancer(NSCLC).
Linked to the drug Iruplinalkib because the registry names it among its interventions and Non-small-cell lung cancer among its conditions. Registry record only: no result has been read by an editor.
Shares Iruplinalkib, ROS1-positive non-small-cell lung cancer, ALK-positive non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Iruplinalkib, ALK-positive non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares ALK-positive non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Resectable stage I to III non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares ROS1-positive non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Resectable stage I to III non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Resectable stage I to III non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Resectable stage I to III non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.